Long-Term Outcome of Phase I/II Clinical Trial of Ad-OC-TK/VAL Gene Therapy for Hormone-Refractory Metastatic Prostate Cancer-Reference-Cited by-同舟云学术

Long-Term Outcome of Phase I/II Clinical Trial of Ad-OC-TK/VAL Gene Therapy for Hormone-Refractory Metastatic Prostate Cancer

Published:2007-12 Issue:12 Volume:18 Page:1225-1232
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Shirakawa Toshiro¹²,Terao Shuji²³,Hinata Nobuyuki²,Tanaka Kazushi²,Takenaka Atsushi²,Hara Isao⁴,Sugimura Kazuro⁵,Matsuo Masafumi⁶,Hamada Katsuyuki⁷,Fuji Kohzo⁸,Okegawa Takatsugu⁹,Higashihara Eiji⁹,Gardner Thomas A.¹⁰,Kao Chinghai¹⁰,Chung Leland W.K.¹¹,Kamidono Sadao¹²,Fujisawa Masato²,Gotoh Akinobu³

Affiliation:

1. International Center for Medical Research and Treatment, Kobe University School of Medicine, Kobe 650-0017, Japan.

2. Division of Urology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

3. Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.

4. Department of Urology, Wakayama Medical University, Wakayama 641-8510, Japan.

5. Division of Radiology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

6. Division of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

7. Department of Obstetrics and Gynecology, Ehime University School of Medicine, Toon City 791-0295, Japan.

8. Department of Urology, Showa University School of Medicine, Tokyo 142-8666, Japan.

9. Department of Urology, University of Kyorin, Tokyo 181-8611, Japan.

10. Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

11. Department of Urology, Emory University School of Medicine, Atlanta, GA 30322, USA.

12. Kobe Red Cross Hospital, Kobe 651-0073, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/hum.2007.074

Reference29 articles.

1. Biological Response Determinants in HSV-tk + Ganciclovir Gene Therapy for Prostate Cancer

2. METABOLIC BONE DISEASE INDUCED BY PROSTATE CANCER: RATIONALE FOR THE USE OF BISPHOSPHONATES

3. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer

4. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients

5. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques;Gene Therapy;2024-07-18

2. Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines;Viruses;2023-12-03

3. Recent advances in gene therapy for cancer theranostics;Current Opinion in Biomedical Engineering;2021-12

4. Viral vector platforms within the gene therapy landscape;Signal Transduction and Targeted Therapy;2021-02-08

5. Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics;Asian Journal of Urology;2019-01